. . . . "2014-06-25+02:00"^^ . . . " DNA" . . . "Projekt splnil sv\u016Fj \u00FA\u010Del. Z\u00EDskan\u00E9 v\u00FDsledky z\u00E1sadn\u00EDm zp\u016Fsobem p\u0159isp\u011Bly k roz\u0161\u00ED\u0159en\u00ED teoretick\u00E9ho z\u00E1zem\u00ED nutn\u00E9ho pro n\u00E1vrhy a v\u00FDvoj nov\u00FDch l\u00E9\u010Div proti rakovin\u011B. V\u00FDstupy tvo\u0159\u00ED 3 impaktovan\u00E9 p\u016Fvodn\u00ED pr\u00E1ce kde je \u0159e\u0161itelka 1x prvn\u00EDm autorem, s celkov\u00FDm IF 14.75. P\u0159edlo\u017Een\u00FD postdoktorsk\u00FD projekt lze hodnotit jako vynikaj\u00EDc\u00ED."@cs . "metallodrugs; iridium; cancer; DNA; cytotoxicity, antitumor effects; mechanism"@en . . " cytotoxicity" . "Project achieved its aims. The obtained results considerably contributed to the improvement of the theoretical background needed for a design of new anticancer drugs. Three IF publications (sum of IF 14.75), where principal investigator was the first author, were published . Solved postdoc project could be considered as excellent."@en . "2011-01-01+01:00"^^ . "http://www.isvav.cz/projectDetail.do?rowId=GPP303/11/P047"^^ . " antitumor effects" . "Molecular and cellular pharmacology of novel class of antitumor iridium complexes. Implications for innovations in cancer chemotherapy"@en . . "Hlavn\u00EDm c\u00EDlem je (i) navrhnout a studovat l\u00E1tky odvozen\u00E9 od komplex\u016F iridia, kter\u00E9 umo\u017En\u00ED obej\u00EDt zn\u00E1m\u00E1 omezen\u00ED souvisej\u00EDc\u00ED s klinick\u00FDm vyu\u017Eit\u00EDm konven\u010Dn\u00ED cisplatiny a jej\u00EDch analog\u016F, na z\u00E1klad\u011B jejich odli\u0161n\u00E9ho p\u016Fsoben\u00ED na molekul\u00E1rn\u00ED a bun\u011B\u010Dn\u00E9 \u00FArovni; (ii) zdokonalit znalosti o efektech nov\u00FDch komplex\u016F iridia na molekul\u00E1rn\u00ED \u00FArovni a srovnat tyto efekty s\u00A0efekty p\u0159\u00EDbuzn\u00FDch komplex\u016F kov\u016F platinov\u00E9 skupiny. Vyu\u017E\u00EDt tyto znalosti s\u00A0c\u00EDlem podpo\u0159it v\u00FDvoj nov\u00FDch metalofarmak. Dal\u0161\u00EDm c\u00EDlem je pokra\u010Dovat v ov\u011B\u0159ov\u00E1n\u00ED t\u00E9to pracovn\u00ED hypot\u00E9zy: \u2018Metalofarmaka, kter\u00E1 se v\u00E1\u017E\u00ED k c\u00EDlov\u00FDm m\u00EDst\u016Fm v bu\u0148ce zp\u016Fsobem z\u00E1sadn\u011B odli\u0161n\u00FDm ve srovn\u00E1n\u00ED s konven\u010Dn\u00EDmi platinov\u00FDmi cytostatiky ji\u017E vyu\u017E\u00EDvan\u00FDmi v klinick\u00E9 praxi, maj\u00ED pozm\u011Bn\u011Bn\u00E9 biologick\u00E9 vlastnosti v\u010Detn\u011B spektra a intenzity protin\u00E1dorov\u00E9 aktivity\u2019. O\u010Dek\u00E1van\u00E9 v\u00FDstupy: Budou navr\u017Eena nov\u00E1 metalofarmaka a z\u00EDsk\u00E1ny \u00FAdaje o souvisej\u00EDc\u00EDch biochemick\u00FDch, molekul\u00E1rn\u011B biologick\u00FDch a farmakologick\u00FDch aspektech jejich p\u016Fsoben\u00ED tak, aby bylo mo\u017En\u00E9 navrhnout nov\u00E9 kandid\u00E1ty \u00FA\u010Dinn\u011Bj\u0161\u00EDch l\u00E9\u010Div proti rakovin\u011B pro klinick\u00E9 zkou\u0161ky." . "metallodrugs" . . . "Molekul\u00E1rn\u00ED a bun\u011B\u010Dn\u00E1 farmakologie nov\u00E9 t\u0159\u00EDdy protin\u00E1dorov\u011B \u00FA\u010Dinn\u00FDch komplex\u016F iridia. Implikace pro inovace v chemoterapii rakoviny" . "GPP303/11/P047" . . " iridium" . . . "0"^^ . . "1"^^ . "The main objectives are (i) to design and study iridium-based agents that circumvent known clinical drawbacks of \u201Cconventional\u201D platinum antitumor drugs already used in the clinic through different molecular-level actions and through molecular targeting; (ii) to enhance our knowledge of the molecular level effects of new iridium-based agents and compare these effects with those of cognate complexes of platinum group metals. To use this knowledge to underpin the process of designing new metallodrugs. Secondary objective is to continue to explore the working hypothesis: \u2018Metal-based drugs, which bind to cellular targets in a fundamentally different manner from that of conventional platinum drugs already used in the clinic, have altered biological properties including spectrum and intensity of antitumor activity\u2019. Major outcome expected: New anticancer metallodrugs will be proposed and the associated biochemistry, molecular biology and pharmacology will be developed and examined to bring novel and more effective drug candidates to clinical trials."@en . " cancer" . . "At the request of the applicant or GACR (not registered in the GACR system)"@en . "2"^^ . "0"^^ . "Na \u017E\u00E1dost \u017Eadatele nebo GA\u010CR (nen\u00ED v syst\u00E9mu GA\u010CR evidov\u00E1no)"@cs . . "2"^^ . "2013-12-31+01:00"^^ . "2013-02-28+01:00"^^ . .